Hypertension related to the antitumor treatment with angiogenesis inhibitors: An iatrogenic hypertension [Артериальная гипертония как кардиотоксическая реакция на противоопухолевую терапию: что мы знаем о новом виде ятрогенной гипертонии]

One of the key regulators of vascular tone is the vascular endothelial growh factor (VEGF), which can enhance the production of nitric oxide, a potent vasodilator, and reduce vascular resistance by generating new vessels. Both mechanisms contribute to blood pressure decrease. The implementation of a new class of antitumor therapy-inhibitors of VEGF signaling pathway-results in the growh of cardiovascular complications such as arterial hypertension (HTN). The paper analyzes the causes of HTN development, approaches to the timely diagnosis of HTN and the correct assessment of cardiovascular risk before administration of VEGF inhibitors and during the treatment. We also review the features of the approaches of elevated blood pressure management in patients receiving targeted therapy. © 2018 All-Russian Public Organization Antihypertensive League. All Rights Reserved.

Publisher
All-Russian Public Organization Antihypertensive League
Number of issue
4
Language
Russian
Pages
384-395
Status
Published
Volume
24
Year
2018
Organizations
  • 1 Peoples' Friendship University of Russia, 6 Miklukho-Maklay street, Moscow, 117198, Russian Federation
Keywords
Cardio-oncology; Hypertension; Tyrosine kinase inhibitors
Date of creation
04.02.2019
Date of change
04.02.2019
Short link
https://repository.rudn.ru/en/records/article/record/36373/
Share

Other records